Literature DB >> 22987279

Giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case.

Masaki Sunagawa1, Masatoshi Isogai, Tohru Harada, Yuji Kaneoka, Keitaro Kamei, Atsuyuki Maeda, Yuichi Takayama.   

Abstract

A 46-year-old female underwent total gastrectomy with a combined resection of the pancreatic tail, spleen, and lateral segment of the liver surgery after conservative medical management for a perforated advanced gastric cancer. The histological findings showed poorly differentiated adenocarcinoma, and the tumor was Stage IIIC. S-1 and "Kampo-Juzen-taiho-to" were administered as postoperative adjuvant chemo-immunotherapy. A Krukenberg tumor was identified 4 years later. The histological findings strongly suggested the presence of peritoneal dissemination, and S-1-based combined chemotherapies using key drugs such as CDDP, CPT-11, and taxane with the biochemical response modifier "Lentinan" was administered. However, the Krukenberg tumor rapidly increased in size after 4 years and she complained of abdominal distension. Therefore, it was removed with neither difficulties nor apparent recurrent disease, which was thought to be due to the S-1-based combined chemotherapy and the immunological agents are likely to have contributed to her long survival and good quality of life.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22987279     DOI: 10.1007/s00595-012-0339-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  12 in total

1.  A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.

Authors:  H Nakano; K Namatame; H Nemoto; H Motohashi; K Nishiyama; K Kumada
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

2.  Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy.

Authors:  Kenji Ina; Ryuichi Furuta; Takae Kataoka; Satoshi Kayukawa; Takashi Yoshida; Takaya Miwa; Yoshitaka Yamamura; Yuuki Takeuchi
Journal:  World J Clin Oncol       Date:  2011-10-10

3.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.

Authors:  Mitsuru Sasako; Shinichi Sakuramoto; Hitoshi Katai; Taira Kinoshita; Hiroshi Furukawa; Toshiharu Yamaguchi; Atsushi Nashimoto; Masashi Fujii; Toshifusa Nakajima; Yasuo Ohashi
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

4.  Retrograde lymphatic spread: a likely route for metastatic ovarian cancers of gastrointestinal origin.

Authors:  T C Chang; C C Changchien; C W Tseng; C H Lai; C J Tseng; S E Lin; C S Wang; K J Huang; H H Chou; Y Y Ma; S Hsueh; H L Eng; H A Fan
Journal:  Gynecol Oncol       Date:  1997-09       Impact factor: 5.482

5.  The challenge of metastatic ovarian carcinoma.

Authors:  S L Israel; E V Helsel; D H Hausman
Journal:  Am J Obstet Gynecol       Date:  1965-12-15       Impact factor: 8.661

6.  The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience.

Authors:  Toshiro Okuyama; Daisuke Korenaga; Kenichi Koushi; Shinji Itoh; Hirofumi Kawanaka; Yasuharu Ikeda; Kenji Takenaka
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

7.  Bu ji (hozai) for treatment of postoperative gastric cancer patients.

Authors:  Y Horie; K Kato; S Kameoka; K Hamano
Journal:  Am J Chin Med       Date:  1994       Impact factor: 4.667

8.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

9.  Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer.

Authors:  Jae Ho Cheong; Woo Jin Hyung; Jian Chen; Junuk Kim; Seung Ho Choi; Sung Hoon Noh
Journal:  J Surg Oncol       Date:  2004-07-15       Impact factor: 3.454

10.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  1 in total

1.  Lentinan: clinical benefit in the management of systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Surg Today       Date:  2013-06-21       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.